Latest Stargardt disease Stories
OXFORD, England, June 22, 2011 /PRNewswire/ -- - RetinoStat(R) Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that the first dose level of RetinoStat(R) is safe and well-tolerated at one month following treatment. RetinoStat(R) is a novel gene-based treatment for neovascular "wet" age-related macular degeneration (AMD), designed and...
The first two patients with common but incurable diseases of the eye that can lead to blindness have been enrolled early in a two phase groundbreaking clinical trial of therapy that researchers are hoping will heal the damage caused by the conditions.
MARLBOROUGH, Mass., June 16, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc.
Slowing down the aggregation or â€œclumpingâ€ of vitamin A in the eye may help prevent vision loss caused by macular degeneration.
MARLBOROUGH, Mass., May 5, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc.
MARLBOROUGH, Mass., April 26, 2011 /PRNewswire/ -- Advanced Cell Technology ("ACT"; OTCBB:ACTC), a leader in the regenerative medicine space, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering a keynote lecture at the 3rd International Collaborative Symposium on Stem Cell Research, April 29-30, in Seoul, South Korea.
MARLBOROUGH, Mass., April 20, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc.
MARLBOROUGH, Mass., March 10, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc.
A Massachusetts-based company has been given Food and Drug Administration (FDA) approval to conduct a trial in which embryonic stem cells will be used to treat individuals suffering from an eye condition that can lead to blindness.
Findings could affect future treatments for macular degeneration, stargardt disease & other forms of retinal disease